Stepwise “bridge-to-bridge” reduction of monoclonal antibodies and light chain detection: case studies of tenatumomab and trastuzumab
Monoclonal antibodies are pharmaceutical products that because of their biological origin are characterized by the presence of countless variants, which are generated by post‐translational modifications, during purification or storage. Among these modifications the disulfide bridges variants are of considerable importance, for example their status can affect the correct Y‐shape of antibody.